Mostra i principali dati dell'item
The emerging role of helicobacter pylori-induced metabolic gastrointestinal dysmotility and neurodegeneration
dc.creator | Kountouras J., Boziki M., Polyzos S.A., Katsinelos P., Gavalas E., Zeglinas C., Tzivras D., Romiopoulos I., Giorgakis N., Anastasiadou K., Vardaka E., Kountouras C., Kazakos E., Giartza-Taxidou E., Deretzi G., Dardiotis E., Kotronis G., Doulberis M. | en |
dc.date.accessioned | 2023-01-31T08:45:27Z | |
dc.date.available | 2023-01-31T08:45:27Z | |
dc.date.issued | 2017 | |
dc.identifier | 10.2174/1566524018666171219094837 | |
dc.identifier.issn | 15665240 | |
dc.identifier.uri | http://hdl.handle.net/11615/75309 | |
dc.description.abstract | Helicobacter pylori infection (Hp-I) is a prevalent disorder identified in themajority of the population in many countries around the world and is responsible for substantial gastrointestinal morbidity. Likewise, neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s diseases, multiple sclerosis or glaucoma defined as ocular Alzheimer’s disease, are associated with a large public health burden and are among the leading causes of disability. Emerging evidences suggest that Hp-I may be associated with neurodegenerative conditions. Moreover, Hp-I could be a predictor of metabolic syndrome (MetS). Hp-I and its related MetS may induce gastrointestinal tract dys-motility disorders with systemic complications possibly including central nervous system neurodegenerative pathologies. We hereby explore the emerging role of Hprelated metabolic gastrointestinal dys-motilities on the molecular pathophysiology of Hprelated neurodegenerative and gastrointestinal disorders. Improving understanding of such Hp-I pathophysiology in brain pathologies may offer benefits by application of new relative therapeutic strategies including novel opportunities toward enhancing Hp eradication. © 2017 Bentham Science Publishers. | en |
dc.language.iso | en | en |
dc.source | Current Molecular Medicine | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85043332112&doi=10.2174%2f1566524018666171219094837&partnerID=40&md5=76b780a0e7b2eba9f175718e8fab7241 | |
dc.subject | anorexigenic agent | en |
dc.subject | arginine | en |
dc.subject | calcitonin | en |
dc.subject | cholecystokinin | en |
dc.subject | glutamine | en |
dc.subject | neuropeptide | en |
dc.subject | proline | en |
dc.subject | proopiomelanocortin | en |
dc.subject | prostaglandin E2 | en |
dc.subject | taurine | en |
dc.subject | tumor necrosis factor | en |
dc.subject | adaptive immunity | en |
dc.subject | Alzheimer disease | en |
dc.subject | amino acid metabolism | en |
dc.subject | axon | en |
dc.subject | carbohydrate metabolism | en |
dc.subject | central nervous system | en |
dc.subject | Creutzfeldt Jakob disease | en |
dc.subject | cryptosporidiosis | en |
dc.subject | dyspepsia | en |
dc.subject | eosinophilic esophagitis | en |
dc.subject | feeding behavior | en |
dc.subject | gastrointestinal disease | en |
dc.subject | gastrointestinal motility disorder | en |
dc.subject | Helicobacter infection | en |
dc.subject | human | en |
dc.subject | infection | en |
dc.subject | innate immunity | en |
dc.subject | intestine flora | en |
dc.subject | irritable colon | en |
dc.subject | Listeria | en |
dc.subject | lymphocyte | en |
dc.subject | median eminence | en |
dc.subject | metabolic syndrome X | en |
dc.subject | microvillus | en |
dc.subject | molecular pathology | en |
dc.subject | nerve degeneration | en |
dc.subject | nonhuman | en |
dc.subject | nose cavity | en |
dc.subject | nuclear magnetic resonance spectroscopy | en |
dc.subject | olfactory system | en |
dc.subject | Parkinson disease | en |
dc.subject | pathophysiology | en |
dc.subject | peripheral nervous system | en |
dc.subject | quality of life | en |
dc.subject | Review | en |
dc.subject | systemic sclerosis | en |
dc.subject | upregulation | en |
dc.subject | animal | en |
dc.subject | complication | en |
dc.subject | degenerative disease | en |
dc.subject | gastrointestinal disease | en |
dc.subject | gastrointestinal motility | en |
dc.subject | Helicobacter infection | en |
dc.subject | Helicobacter pylori | en |
dc.subject | isolation and purification | en |
dc.subject | microbiology | en |
dc.subject | pathogenicity | en |
dc.subject | prevalence | en |
dc.subject | Animals | en |
dc.subject | Gastrointestinal Diseases | en |
dc.subject | Gastrointestinal Motility | en |
dc.subject | Helicobacter Infections | en |
dc.subject | Helicobacter pylori | en |
dc.subject | Humans | en |
dc.subject | Neurodegenerative Diseases | en |
dc.subject | Prevalence | en |
dc.subject | Bentham Science Publishers B.V. | en |
dc.title | The emerging role of helicobacter pylori-induced metabolic gastrointestinal dysmotility and neurodegeneration | en |
dc.type | other | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |